Amendment to Amended and Restated Agreement Sample Contracts
Amendment to Amended and Restated Agreement Between Genentech, Inc. and F. Hoffmann-La Roche Ltd Regarding Commercialization of Genentech's Products Outside the United StatesAmendment to Amended and Restated Agreement • July 27th, 2004 • Genentech Inc • Pharmaceutical preparations
This Amendment to Amended and Restated Agreement Between Genentech, Inc. and F. Hoffmann-La Roche Ltd Regarding Commercialization of Genentech's Products Outside the United States (hereinafter, "Amendment") is made, effective as of March 10, 2000 ("Amendment Effective Date"), by and among F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland ("ROCHE"), Genentech, Inc., 1 DNA Way, South San Francisco, California USA 94080, Genentech Europe Limited, Reid House, 31 Church Street, Hamilton, Bermuda HM FXV and Genentech Biopharmaceuticals Limited, Reid House, 31 Church Street, Hamilton, Bermuda HM FXV ("GENENTECH").
AMENDMENT TO AMENDED AND RESTATED AGREEMENTAmendment to Amended and Restated Agreement • November 10th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment to Amended and Restated Agreement (this “Amendment”) is entered into as of August 9, 2021 (the “Amendment Effective Date”) by and between Finch Therapeutics, Inc., a Delaware corporation having its principal office at 200 Inner Belt Road, 4th Floor, Somerville, Massachusetts 02143 (“Finch”), and Takeda Development Center Americas, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal office at 95 Hayden Avenue, Lexington, MA 02421 (“Takeda”).
AMENDMENT #2 TO AMENDED AND RESTATED AGREEMENTAmendment to Amended and Restated Agreement • March 31st, 2022 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment to Amended and Restated Agreement (this “Amendment”) is entered into as of November 12, 2021 (the “Amendment #2 Effective Date”) by and between Finch Therapeutics, Inc., a Delaware corporation having its principal office at 200 Inner Belt Road, 4th Floor, Somerville, Massachusetts 02143 (“Finch”), and Takeda Development Center Americas, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal office at 95 Hayden Avenue, Lexington, MA 02421 (“Takeda”).
AMENDMENT TO AMENDED AND RESTATED AGREEMENT OF DECEMBER 31, 1998Amendment to Amended and Restated Agreement • June 30th, 2006 • Bare Escentuals Inc • Pennsylvania
THIS AMENDMENT TO AMENDED AND RESTATED AGREEMENT OF DECEMBER 31, 1998 (“Amendment”) is effective as of January 29, 1999 by and between QVC, Inc., a Delaware corporation (“QVC”) and Dolphin Acquisition Corp., a California corporation (“Company”).
AMENDMENT TO AMENDED AND RESTATED AGREEMENTAmendment to Amended and Restated Agreement • March 17th, 2011 • Document Security Systems Inc • Services-computer integrated systems design
THIS AMENDMENT TO AMENDED AND RESTATED AGREEMENT (the “Amendment”) dated as of March 14, 2011, is entered into by and between Document Security Systems, Inc., a New York corporation (together with its successors, the "Company"), and Fletcher International, Ltd., a company domiciled in Bermuda (together with its successors, the "Purchaser"). Capitalized terms used but not otherwise defined herein shall have the respective meanings set forth in the Agreement (as defined below), as applicable.
Amendment to Amended and Restated Agreement Between Genentech, Inc. and F. Hoffmann-LaRoche Ltd Regarding Commercialization of Genentech's Products Outside the United StatesAmendment to Amended and Restated Agreement • July 27th, 2004 • Genentech Inc • Pharmaceutical preparations
This Amendment to Amended and Restated Agreement Between Genentech, Inc. and F. Hoffmann-LaRoche Ltd Regarding Commercialization of Genentech's Products Outside the United States (hereinafter, "Amendment") is made, effective as of June 26, 2000 ("Amendment Effective Date"), by and among F. Hoffmann-LaRoche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland ("ROCHE"), Genentech, Inc., 1 DNA Way, South San Francisco, California USA 94080, Genentech Europe Limited, Reid House, 31 Church Street, Hamilton, Bermuda HM FXV and Genentech Biopharmaceuticals Limited, Reid House, 31 Church Street, Hamilton, Bermuda HM FXV ("GENENTECH").